CORBILTA

This brand name is authorized in Austria, Croatia, Estonia, France, Italy, Lithuania, Netherlands, Poland.

Active ingredients

The drug CORBILTA contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII MNX7R8C5VO - CARBIDOPA
 

Carbidopa is a peripheral aromatic amino acid decarboxylase inhibitor. It prevents metabolism of levodopa to dopamine in the peripheral circulation, ensuring that a higher proportion of the dose reaches the brain, where dopamine exerts its therapeutic effects. A lower dose of levodopa can be used when it is coadministered with carbidopa, reducing the incidence and severity of peripheral side effects.

 
Read more about Carbidopa
2
UNII 4975G9NM6T - ENTACAPONE
 

Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa.

 
Read more about Entacapone
3
UNII 46627O600J - LEVODOPA
 

According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.

 
Read more about Levodopa

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 CORBILTA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
N04BA03 Levodopa, decarboxylase inhibitor and COMT inhibitor N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BA Dopa and dopa derivatives
Discover more medicines within N04BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1632237, 1632248, 1632259, 1632260, 1632271, 1699780, 1699791, 1699803, 1699814, 1699825, 1699836, 1699847, 1699858, 1699869, 1699870, 1699881, 1699892, 1699904, 1699915, 1699926, 1699937, 1699948, 1699959, 1699960, 1699971, 1699982, 1699993, 1700008, 1700019, 1700020, 1700031, 1700042, 1700053, 1700064, 1700075, 1700086, 1700097
FR Base de données publique des médicaments 67719818, 69355498
IT Agenzia del Farmaco 043152038, 043152091, 043152141, 043152204, 043152255, 043152368
LT Valstybinė vaistų kontrolės tarnyba 1072027, 1072028, 1072029, 1072030, 1072031, 1072032, 1072033, 1072034, 1072035, 1072036, 1072037, 1072038, 1072039, 1072040, 1072041, 1072042, 1072043, 1072044, 1072045, 1072046, 1072047, 1072048, 1072049, 1072050, 1072051, 1072052, 1072053, 1072054, 1072055, 1072056, 1072057, 1072058, 1072059, 1072060, 1072061, 1072062, 1072063, 1072064
NL Z-Index G-Standaard, PRK 119938, 119946, 119954, 86703, 89680, 89699
PL Rejestru Produktów Leczniczych 100311493, 100311501, 100311518, 100311524, 100311530, 100311547, 100311553

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.